ZD 1839 in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck
Completed · Phase 2
Conditions studied: Head and Neck Cancer
In brief
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of head and neck cancer. PURPOSE: Phase II trial to study the effectiveness of ZD1839 in treating patients who have metastatic or recurrent cancer of the head and neck.
Key facts
- Study ID
- NCT00015964
- Run by
- University of Chicago
- People needed
- 51
- Starts
- 2001-03-01
- Expected to finish
- 2005-07-01
- Last updated by the study team
- 2013-09-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Chicago Cancer Research Center — Chicago, Illinois, United States
- Louis A. Weiss Memorial Hospital — Chicago, Illinois, United States
- Cancer Care Specialists of Central Illinois, S.C. — Decatur, Illinois, United States
- Evanston Northwestern Health Care — Evanston, Illinois, United States
- Ingalls Memorial Hospital — Harvey, Illinois, United States
- Columbia LaGrange Memorial Hospital — LaGrange, Illinois, United States
- Loyola University Medical Center — Maywood, Illinois, United States
- Oncology/Hematology Associates of Central Illinois, P.C. — Peoria, Illinois, United States
- Fort Wayne Medical Oncology and Hematology, Inc. — Fort Wayne, Indiana, United States
- Michiana Hematology/Oncology P.C. — South Bend, Indiana, United States
- Oncology Care Associates, P.L.L.C. — Saint Joseph, Michigan, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.